Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) was estimated to be worth US$ 14380 million in 2023 and is forecast to a readjusted size of US$ 56720 million by 2030 with a CAGR of 21.4% during the forecast period 2024-2030
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by region & country, by Type, and by Application.
The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Market Segmentation
By Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Segment by Type:
CellSearch
Others
Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Introduction
1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Forecast
1.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends & Drivers
1.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
1.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers & Opportunity
1.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
1.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Ranking (2023)
2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Company (2019-2024)
2.3 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Offered
2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
2.6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Analysis
2.6.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CellSearch
3.1.2 Others
3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type
3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (2019-2030)
3.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Breast Cancer Diagnosis and Treatment
4.1.2 Prostate Cancer Diagnosis and Treatment
4.1.3 Colorectal Cancer Diagnosis and Treatment
4.1.4 Lung Cancer Diagnosis and Treatment
4.1.5 Other Cancers Diagnosis and Treatment
4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application
4.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (2019-2030)
4.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region
5.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2019-2024)
5.1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2025-2030)
5.1.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.2.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.4.2 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.5.2 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.6.2 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value
6.3 United States
6.3.1 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.3.2 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.4.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.5.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.6.2 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.7.2 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.8.2 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.9.2 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Janssen
7.1.1 Janssen Profile
7.1.2 Janssen Main Business
7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.1.5 Janssen Recent Developments
7.2 Qiagen
7.2.1 Qiagen Profile
7.2.2 Qiagen Main Business
7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.2.5 Qiagen Recent Developments
7.3 Advanced Cell Diagnostics
7.3.1 Advanced Cell Diagnostics Profile
7.3.2 Advanced Cell Diagnostics Main Business
7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.3.5 ApoCell Recent Developments
7.4 ApoCell
7.4.1 ApoCell Profile
7.4.2 ApoCell Main Business
7.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.4.5 ApoCell Recent Developments
7.5 Biofluidica
7.5.1 Biofluidica Profile
7.5.2 Biofluidica Main Business
7.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.5.5 Biofluidica Recent Developments
7.6 Clearbridge Biomedics
7.6.1 Clearbridge Biomedics Profile
7.6.2 Clearbridge Biomedics Main Business
7.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.6.5 Clearbridge Biomedics Recent Developments
7.7 CytoTrack
7.7.1 CytoTrack Profile
7.7.2 CytoTrack Main Business
7.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.7.5 CytoTrack Recent Developments
7.8 Celsee
7.8.1 Celsee Profile
7.8.2 Celsee Main Business
7.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.8.5 Celsee Recent Developments
7.9 Fluxion
7.9.1 Fluxion Profile
7.9.2 Fluxion Main Business
7.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.9.5 Fluxion Recent Developments
7.10 Gilupi
7.10.1 Gilupi Profile
7.10.2 Gilupi Main Business
7.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.10.5 Gilupi Recent Developments
7.11 Cynvenio
7.11.1 Cynvenio Profile
7.11.2 Cynvenio Main Business
7.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.11.5 Cynvenio Recent Developments
7.12 On-chip
7.12.1 On-chip Profile
7.12.2 On-chip Main Business
7.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.12.5 On-chip Recent Developments
7.13 YZY Bio
7.13.1 YZY Bio Profile
7.13.2 YZY Bio Main Business
7.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.13.5 YZY Bio Recent Developments
7.14 BioView
7.14.1 BioView Profile
7.14.2 BioView Main Business
7.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.14.5 BioView Recent Developments
7.15 Fluidigm
7.15.1 Fluidigm Profile
7.15.2 Fluidigm Main Business
7.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.15.5 Fluidigm Recent Developments
7.16 Ikonisys
7.16.1 Ikonisys Profile
7.16.2 Ikonisys Main Business
7.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.16.5 Ikonisys Recent Developments
7.17 AdnaGen
7.17.1 AdnaGen Profile
7.17.2 AdnaGen Main Business
7.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.17.5 AdnaGen Recent Developments
7.18 IVDiagnostics
7.18.1 IVDiagnostics Profile
7.18.2 IVDiagnostics Main Business
7.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.18.5 IVDiagnostics Recent Developments
7.19 Miltenyi Biotec
7.19.1 Miltenyi Biotec Profile
7.19.2 Miltenyi Biotec Main Business
7.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.19.5 Miltenyi Biotec Recent Developments
7.20 ScreenCell
7.20.1 ScreenCell Profile
7.20.2 ScreenCell Main Business
7.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.20.5 ScreenCell Recent Developments
7.21 Silicon Biosystems
7.21.1 Silicon Biosystems Profile
7.21.2 Silicon Biosystems Main Business
7.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.21.5 Silicon Biosystems Recent Developments
8 Industry Chain Analysis
8.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industrial Chain
8.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Model
8.5.2 Sales Channel
8.5.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
听
听
*If Applicable.
